Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia

Results from the United States Registry for Fibromuscular Dysplasia

Ido Weinberg, Xiaokui Gu, Jay Giri, Soo E. Kim, Michael J. Bacharach, Bruce H. Gray, Barry T. Katzen, Alan H. Matsumoto, Yung-wei Chi, Kevin R. Rogers, James Froehlich, Jeffrey W. Olin, Heather L. Gornik, Michael R. Jaff

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Fibromuscular dysplasia (FMD), a non-inflammatory arterial disease, may lead to renovascular hypertension (HTN) and cerebrovascular disease. Little is known about medication use in FMD. Clinical features and medication use were reviewed in a national FMD registry (12 US sites). Medication usage was assessed in raw and adjusted analyses. Covariates included demographic characteristics, co-morbid conditions and vascular bed involvement. A total of 874 subjects (93.6% female) were included in the analysis. Mean age was 55.6±13.1 years, 74.5% had HTN, 25.4% had a history of transient ischemic attack or stroke, and 7.5% had a history of coronary artery disease (CAD). Renal and cerebrovascular arteries were affected in 70.4% and 74.7%, respectively. Anti-platelet agents were administered to 72.9% of patients. In multivariate analyses, factors associated with a greater likelihood of anti-platelet agent use were older age (OR=1.02 per year, p=0.005), CAD (OR=3.76, p=0.015), cerebrovascular artery FMD involvement in isolation (OR=2.31, p

Original languageEnglish (US)
Pages (from-to)447-453
Number of pages7
JournalVascular Medicine (United Kingdom)
Volume20
Issue number5
DOIs
StatePublished - Oct 1 2015

Fingerprint

Fibromuscular Dysplasia
Registries
Blood Platelets
Hypertension
Coronary Artery Disease
Cerebrovascular Disorders
Renovascular Hypertension
Transient Ischemic Attack
Renal Artery
Blood Vessels
Multivariate Analysis
Stroke
Demography

Keywords

  • anti-platelet
  • fibromuscular dysplasia
  • FMD
  • hypertension
  • medication

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia : Results from the United States Registry for Fibromuscular Dysplasia. / Weinberg, Ido; Gu, Xiaokui; Giri, Jay; Kim, Soo E.; Bacharach, Michael J.; Gray, Bruce H.; Katzen, Barry T.; Matsumoto, Alan H.; Chi, Yung-wei; Rogers, Kevin R.; Froehlich, James; Olin, Jeffrey W.; Gornik, Heather L.; Jaff, Michael R.

In: Vascular Medicine (United Kingdom), Vol. 20, No. 5, 01.10.2015, p. 447-453.

Research output: Contribution to journalArticle

Weinberg, I, Gu, X, Giri, J, Kim, SE, Bacharach, MJ, Gray, BH, Katzen, BT, Matsumoto, AH, Chi, Y, Rogers, KR, Froehlich, J, Olin, JW, Gornik, HL & Jaff, MR 2015, 'Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia: Results from the United States Registry for Fibromuscular Dysplasia', Vascular Medicine (United Kingdom), vol. 20, no. 5, pp. 447-453. https://doi.org/10.1177/1358863X15584982
Weinberg, Ido ; Gu, Xiaokui ; Giri, Jay ; Kim, Soo E. ; Bacharach, Michael J. ; Gray, Bruce H. ; Katzen, Barry T. ; Matsumoto, Alan H. ; Chi, Yung-wei ; Rogers, Kevin R. ; Froehlich, James ; Olin, Jeffrey W. ; Gornik, Heather L. ; Jaff, Michael R. / Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia : Results from the United States Registry for Fibromuscular Dysplasia. In: Vascular Medicine (United Kingdom). 2015 ; Vol. 20, No. 5. pp. 447-453.
@article{92f3799f110a4288bd8760304940bb4b,
title = "Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia: Results from the United States Registry for Fibromuscular Dysplasia",
abstract = "Fibromuscular dysplasia (FMD), a non-inflammatory arterial disease, may lead to renovascular hypertension (HTN) and cerebrovascular disease. Little is known about medication use in FMD. Clinical features and medication use were reviewed in a national FMD registry (12 US sites). Medication usage was assessed in raw and adjusted analyses. Covariates included demographic characteristics, co-morbid conditions and vascular bed involvement. A total of 874 subjects (93.6{\%} female) were included in the analysis. Mean age was 55.6±13.1 years, 74.5{\%} had HTN, 25.4{\%} had a history of transient ischemic attack or stroke, and 7.5{\%} had a history of coronary artery disease (CAD). Renal and cerebrovascular arteries were affected in 70.4{\%} and 74.7{\%}, respectively. Anti-platelet agents were administered to 72.9{\%} of patients. In multivariate analyses, factors associated with a greater likelihood of anti-platelet agent use were older age (OR=1.02 per year, p=0.005), CAD (OR=3.76, p=0.015), cerebrovascular artery FMD involvement in isolation (OR=2.31, p",
keywords = "anti-platelet, fibromuscular dysplasia, FMD, hypertension, medication",
author = "Ido Weinberg and Xiaokui Gu and Jay Giri and Kim, {Soo E.} and Bacharach, {Michael J.} and Gray, {Bruce H.} and Katzen, {Barry T.} and Matsumoto, {Alan H.} and Yung-wei Chi and Rogers, {Kevin R.} and James Froehlich and Olin, {Jeffrey W.} and Gornik, {Heather L.} and Jaff, {Michael R.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1177/1358863X15584982",
language = "English (US)",
volume = "20",
pages = "447--453",
journal = "Vascular Medicine (United Kingdom)",
issn = "1358-863X",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia

T2 - Results from the United States Registry for Fibromuscular Dysplasia

AU - Weinberg, Ido

AU - Gu, Xiaokui

AU - Giri, Jay

AU - Kim, Soo E.

AU - Bacharach, Michael J.

AU - Gray, Bruce H.

AU - Katzen, Barry T.

AU - Matsumoto, Alan H.

AU - Chi, Yung-wei

AU - Rogers, Kevin R.

AU - Froehlich, James

AU - Olin, Jeffrey W.

AU - Gornik, Heather L.

AU - Jaff, Michael R.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Fibromuscular dysplasia (FMD), a non-inflammatory arterial disease, may lead to renovascular hypertension (HTN) and cerebrovascular disease. Little is known about medication use in FMD. Clinical features and medication use were reviewed in a national FMD registry (12 US sites). Medication usage was assessed in raw and adjusted analyses. Covariates included demographic characteristics, co-morbid conditions and vascular bed involvement. A total of 874 subjects (93.6% female) were included in the analysis. Mean age was 55.6±13.1 years, 74.5% had HTN, 25.4% had a history of transient ischemic attack or stroke, and 7.5% had a history of coronary artery disease (CAD). Renal and cerebrovascular arteries were affected in 70.4% and 74.7%, respectively. Anti-platelet agents were administered to 72.9% of patients. In multivariate analyses, factors associated with a greater likelihood of anti-platelet agent use were older age (OR=1.02 per year, p=0.005), CAD (OR=3.76, p=0.015), cerebrovascular artery FMD involvement in isolation (OR=2.31, p

AB - Fibromuscular dysplasia (FMD), a non-inflammatory arterial disease, may lead to renovascular hypertension (HTN) and cerebrovascular disease. Little is known about medication use in FMD. Clinical features and medication use were reviewed in a national FMD registry (12 US sites). Medication usage was assessed in raw and adjusted analyses. Covariates included demographic characteristics, co-morbid conditions and vascular bed involvement. A total of 874 subjects (93.6% female) were included in the analysis. Mean age was 55.6±13.1 years, 74.5% had HTN, 25.4% had a history of transient ischemic attack or stroke, and 7.5% had a history of coronary artery disease (CAD). Renal and cerebrovascular arteries were affected in 70.4% and 74.7%, respectively. Anti-platelet agents were administered to 72.9% of patients. In multivariate analyses, factors associated with a greater likelihood of anti-platelet agent use were older age (OR=1.02 per year, p=0.005), CAD (OR=3.76, p=0.015), cerebrovascular artery FMD involvement in isolation (OR=2.31, p

KW - anti-platelet

KW - fibromuscular dysplasia

KW - FMD

KW - hypertension

KW - medication

UR - http://www.scopus.com/inward/record.url?scp=84943176426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943176426&partnerID=8YFLogxK

U2 - 10.1177/1358863X15584982

DO - 10.1177/1358863X15584982

M3 - Article

VL - 20

SP - 447

EP - 453

JO - Vascular Medicine (United Kingdom)

JF - Vascular Medicine (United Kingdom)

SN - 1358-863X

IS - 5

ER -